RxDoctor Payments DataLook up a doctor →

Jessica Chism, MD

Rheumatology · Fayetteville, ARNPI 1386868545

Payments from drug & device makers

$12,076in general payments, 2019–2025

Across 745 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AbbVie$2K
  • Pfizer$898
  • UCB, Inc.$738
  • Johnson & Johnson$580
  • E.r. Squibb & Sons, L.L.C.$539
  • plus $3K from 20 others

What the payments were for

  • Food & beverage$11,99899%
  • Education$771%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,076 in reported general payments places this provider in the 65th percentile of 48 rheumatology providers in Arkansas.

See all rheumatology providers in Arkansas

Medicare billing

Part B allowed, 2024
$89,902
Medicare patients
308
Services billed
1,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Orencia ClickjectAbatacept116$657,105
RinvoqUpadacitinib87$563,442
Enbrel SureclickEtanercept44$317,824
StelaraUstekinumab11$260,898
Humira(Cf) PenAdalimumab26$194,933
SimponiGolimumab27$181,341
Taltz AutoinjectorIxekizumab17$175,937
Actemra ActpenTocilizumab32$139,375
OtezlaApremilast26$123,802
KevzaraSarilumab27$118,979
EnbrelEtanercept19$97,731
Cosentyx Sensoready (2 Pens)Secukinumab11$79,843
ActemraTocilizumab13$62,308
Hydroxychloroquine Sulfate616$16,058
MethotrexateMethotrexate Sodium460$10,890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$2,457$563,44287 claims
Johnson & JohnsonStelara, Simponi$580$442,23938 claims
AmgenOtezla, Enbrel$3,414$221,53345 claims
SanofiKevzara$70$118,97927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 48 rheumatology providers in Arkansas.

Other rheumatology in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →